Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Researchers identify biomarkers that could be targets for novel drugs to treat glioblastoma

Researchers identify biomarkers that could be targets for novel drugs to treat glioblastoma

Conceptual framework to examine the patterns of copy number alterations in human cancer

Conceptual framework to examine the patterns of copy number alterations in human cancer

Researchers identify a signature of three genes linked to positive response to blood cancer therapy

Researchers identify a signature of three genes linked to positive response to blood cancer therapy

Combination of three technologies makes potential treatment effective against aggressive brain tumor

Combination of three technologies makes potential treatment effective against aggressive brain tumor

Treatment with immunity-boosting protein enhances the function of CAR-T cells in fighting blood cancers

Treatment with immunity-boosting protein enhances the function of CAR-T cells in fighting blood cancers

New molecule kills a broad spectrum of hard-to-treat cancers

New molecule kills a broad spectrum of hard-to-treat cancers

Proteomic analysis of 2002 tumors reveals 11 distinct pan-cancer molecular subtypes

Proteomic analysis of 2002 tumors reveals 11 distinct pan-cancer molecular subtypes

New compound shows promise to kill a range of hard-to-treat cancer types

New compound shows promise to kill a range of hard-to-treat cancer types

Novel photonic technology could enable fluorescent sensors to track molecules deep inside the body

Novel photonic technology could enable fluorescent sensors to track molecules deep inside the body

New MRI nanotechnology designed to precisely image aggressive brain tumors

New MRI nanotechnology designed to precisely image aggressive brain tumors

Rutgers study identifies key protein for brain stem cell longevity

Rutgers study identifies key protein for brain stem cell longevity

Research suggests a new approach to treating Glioblastoma Multiforme in adults

Research suggests a new approach to treating Glioblastoma Multiforme in adults

Novel magnetic therapy complements chemotherapy to enhance breast cancer treatment outcomes

Novel magnetic therapy complements chemotherapy to enhance breast cancer treatment outcomes

Johns Hopkins scientists receive $7.8 million funding from Break Through Cancer

Johns Hopkins scientists receive $7.8 million funding from Break Through Cancer

MD Anderson awarded more than $10 million in grants to support collaborative cancer research

MD Anderson awarded more than $10 million in grants to support collaborative cancer research

A comprehensive rule book for the design of safe and efficient therapeutic cells

A comprehensive rule book for the design of safe and efficient therapeutic cells

Scientists discover differences in interaction of T-cells within tumor microenvironments

Scientists discover differences in interaction of T-cells within tumor microenvironments

Harnessing electricity to treat certain types of cancer

Harnessing electricity to treat certain types of cancer

Novel therapy advances to clinical trial for the treatment of glioblastoma

Novel therapy advances to clinical trial for the treatment of glioblastoma

City of Hope's late-breaking clinical trial data to be presented at AACR

City of Hope's late-breaking clinical trial data to be presented at AACR

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.